attenu
measl
viru
mv
one
effect
safe
vaccin
avail
make
attract
candid
vector
prevent
infecti
diseas
attenu
mv
acquir
abil
use
complement
regul
major
receptor
mediat
viru
entri
intercellular
fusion
therefor
attenu
mv
strain
preferenti
infect
destroy
wide
varieti
cancer
cell
make
also
attract
oncolyt
vector
use
recombin
mv
vector
compli
variou
regulatori
requir
particularli
relat
assess
potenti
risk
human
health
environ
present
articl
highlight
main
characterist
mv
recombin
mv
vector
use
vaccin
virotherapi
discuss
featur
biosafeti
point
view
attenu
measl
viru
mv
repres
attract
vector
candid
virotherapi
vaccin
due
sever
featur
includ
impress
track
record
safeti
efficaci
human
popul
ii
lack
genom
integr
host
cell
due
cytoplasm
replic
iii
high
immunogen
vaccin
iv
compar
rna
virus
mv
maintain
high
level
genet
stabil
v
larg
foreign
gene
insert
capac
kb
vi
select
tumor
cell
case
virotherapi
applic
mani
attenu
strain
use
deriv
mv
edmonston
strain
mvedm
isol
throat
wash
blood
child
measl
primari
cultur
human
kidney
cell
isol
subsequ
adapt
variou
type
cultur
cell
give
rise
attenu
edmonston
b
seed
passag
edmonston
b
seed
chicken
embryo
fibroblast
cef
produc
attenu
schwarz
moraten
virus
tabl
summar
characterist
differ
measl
vaccin
strain
deriv
edmonston
strain
administr
vaccin
dramat
reduc
incid
measl
vaccin
among
effect
safe
human
vaccin
use
provid
longlast
protect
characterist
make
measl
vaccin
attract
viral
vector
backbon
develop
recombin
vaccin
viral
infect
human
immunodefici
viru
hiv
sar
coronaviru
sarscov
flaviviru
infect
nucleotid
differ
differ
attenu
vaccin
strain
use
vector
mvedm
indic
tabl
attenu
determin
absolut
number
substitut
zagreb
strain
attenu
edmonston
b
strain
fewer
substitut
compar
mvedm
schwarz
moraten
strain
ident
nucleotid
sequenc
despit
diverg
passag
histori
strain
passag
cef
reduc
temperatur
possibl
similar
cell
cultur
condit
may
result
similar
nucleotid
substitut
despit
divers
geograph
origin
progenitor
variat
cell
cultur
system
incub
temperatur
passag
number
genom
vaccin
demonstr
sequenc
similar
choic
strain
design
recombin
vector
base
attenu
strain
safe
use
vaccin
rather
nucleotid
sequenc
analysi
measl
vaccin
deriv
wildtyp
progenitor
isol
independ
russia
japan
cam
china
wildtyp
wt
mv
enter
cell
predominantli
via
signal
lymphocyt
activ
molecul
slam
also
known
mainli
express
subset
lymphocyt
thymocyt
macrophag
matur
dendrit
cell
dc
contrast
laboratori
adapt
attenu
mvedm
strain
acquir
abil
use
besid
complement
regul
also
known
membran
cofactor
protein
mcp
receptor
mediat
viru
entri
intercellular
fusion
receptor
overexpress
surfac
malign
cell
protect
complement
mediat
cell
lysi
anoth
cellular
receptor
also
known
polioviru
receptorlik
protein
express
primari
airway
epitheli
cell
also
overexpress
mani
tumor
type
also
identifi
receptor
mv
viral
entri
therefor
attenu
mv
strain
preferenti
infect
destroy
wide
varieti
cancer
cell
make
attract
oncolyt
vector
recombin
attenu
mv
strain
current
test
sever
phase
clinic
trial
vaccin
hiv
chikungunya
viru
oncolyt
vector
ovarian
cancer
glioblastoma
multiform
multipl
myeloma
head
neck
cancer
mesothelioma
use
recombin
genet
modifi
gm
viral
vector
preclin
clinic
trial
must
compli
sever
european
union
legisl
includ
legal
provis
biosafeti
aim
protect
public
health
environ
potenti
advers
effect
genet
modifi
organ
activ
involv
manipul
gm
viral
vector
contain
condit
eg
laboratori
anim
husbandri
product
facil
hospit
room
may
compli
direct
activ
involv
deliber
releas
environ
requir
casebycas
environment
risk
assess
era
carri
releas
accord
principl
defin
annex
ii
direct
era
also
part
procedur
market
author
gener
step
underli
era
viral
vector
discuss
baldo
et
al
articl
focus
biosafeti
issu
european
union
perform
clinic
trial
recombin
attenu
mv
vector
risk
relat
research
develop
activ
larg
scale
product
vector
develop
present
review
measl
viru
envelop
negativestrand
rna
viru
genu
morbilliviru
within
paramyxovirida
famili
caus
agent
acut
exanthem
infecti
measl
diseas
mv
genom
encod
protein
nonstructur
protein
v
c
phosphoprotein
p
larg
polymeras
protein
l
nucleoprotein
n
form
viral
nucleocapsid
contain
viral
rna
genom
matrix
protein
envelop
glycoprotein
hemagglutinin
protein
h
fusion
protein
f
respons
receptor
bind
membran
fusion
respect
upon
infect
suscept
cell
mv
caus
cellcel
fusion
produc
multinucl
giant
cell
typic
cytopath
effect
mv
infect
infect
natur
rout
initi
respiratori
tract
via
infect
c
alveolar
macrophag
dc
airway
lumen
epitheli
cell
layer
receptormedi
recognit
mv
measl
viru
captur
dc
wide
distribut
throughout
respiratori
epithelium
instead
degrad
mv
protect
transport
region
lymph
node
effici
transmit
c
lymphocyt
amplifi
viru
establish
primari
viremia
amplif
viru
lymph
node
lymphocyt
monocyt
carri
viru
variou
organ
throughout
bodi
includ
skin
kidney
gastrointestin
tract
liver
throughout
respiratori
tract
mvinfect
lymphocyt
migrat
lung
tissu
blood
vessel
may
induc
degrad
basement
membran
travel
adjac
epitheli
cell
transmit
viru
epitheli
cell
via
receptor
express
adheren
junction
caus
extens
epitheli
damag
apic
shed
mv
result
transmiss
next
host
human
known
natur
host
mv
nonhuman
primat
also
infect
commonli
use
model
infect
date
known
anim
reservoir
asymptomat
carrier
state
document
measl
rubeola
one
contagi
viral
diseas
known
measl
viru
effici
transmit
aerosol
enter
respiratori
tract
direct
contact
respiratori
secret
capac
spread
high
one
person
infect
mv
infect
other
mean
interrupt
endem
transmiss
popul
requir
popul
immun
infecti
dose
wt
mv
unit
intranas
spray
measl
viru
cytoplasm
replic
cycl
elimin
possibl
integr
host
cell
dna
possibl
insert
mutagenesi
measl
viru
envelop
viru
unstabl
environ
surviv
less
hour
surfac
object
respiratori
droplet
remain
infect
least
one
hour
confin
space
mv
suscept
varieti
disinfect
eg
povidon
iodin
sodium
hypochlorit
peracet
acid
hydrogen
peroxid
ethanol
world
health
organ
defin
criteria
classif
microorgan
risk
group
take
account
sever
diseas
pathogen
may
caus
human
anim
abil
spread
among
popul
avail
prophylaxi
effici
treatment
belgium
classif
list
human
anim
plant
pathogen
provid
tool
identifi
biolog
hazard
associ
contain
use
wildtyp
pathogen
organ
mv
classifi
biolog
agent
class
risk
human
caus
human
diseas
might
hazard
directli
expos
person
howev
unlik
spread
commun
effect
prophylact
vaccin
measl
avail
attenu
mv
strain
result
adapt
viru
growth
condit
nonpermiss
cell
cultur
especi
avian
cell
line
mv
isol
passag
neg
cell
human
kidney
cell
vero
cell
may
select
virus
capabl
use
receptor
viral
entri
host
cell
use
mv
strain
may
consid
vitro
adapt
rather
vivo
properti
strain
likewis
vaccin
strain
must
adapt
chicken
embryo
fibroblast
use
unknown
receptor
present
complement
regulatori
protein
play
import
role
protect
autolog
cell
complement
attack
ubiquit
express
low
densiti
normal
human
cell
type
except
erythrocyt
level
tumor
cell
fold
higher
compar
normal
cell
protect
tumor
cell
complement
mediat
lysi
high
receptor
densiti
tumor
cell
key
determin
oncolyt
specif
attenu
mv
strain
wherea
viru
entri
increas
progress
densiti
threshold
number
receptor
requir
celltocel
fusion
lead
death
cell
incorpor
syncytia
differenti
express
tumor
cell
versu
normal
cell
significantli
increas
suscept
tumor
cell
oncolyt
activ
mv
attenu
strain
vivo
tropism
attenu
mv
wt
mv
compar
use
anim
model
cynomoglu
macaqu
experiment
infect
via
intratrach
aerosol
rout
wt
mv
caus
signific
viremia
viral
dissemin
skin
submucosa
respiratori
epithelia
mv
strain
acquir
abil
use
receptor
might
gain
growth
advantag
vitro
human
monkey
cell
distribut
ubiquit
unlik
howev
vivo
mv
attenu
strain
downregul
infect
cell
subject
complementmedi
cell
lysi
may
limit
spread
mv
infect
vitro
attenu
mv
much
wider
tropism
wt
mv
use
cellular
receptor
enter
host
cell
third
mv
receptor
express
abundantli
placent
trophoblast
glandular
cell
stomach
adenocarcinoma
lung
breast
ovari
moder
amount
express
epithelium
tonsil
oral
mucosa
esophagu
epitheli
cell
nasopharynx
trachea
express
adheren
junction
basolater
side
epitheli
cell
close
contact
infect
mv
lymphocyt
dendrit
cell
necessari
infect
human
airway
epithelia
smaller
amount
express
lung
macrophag
neuron
cell
cerebr
cortex
cancer
cell
highli
upregul
express
apic
basolater
surfac
revers
genet
technolog
use
helpercellbas
rescu
system
allow
rescu
replic
measl
virus
clone
dna
abl
stabli
express
heterolog
antigen
technolog
enabl
rescu
clinic
approv
genet
relev
measl
vaccin
strain
edmonston
b
strain
use
construct
essenti
genet
modifi
oncolyt
mvedm
deriv
describ
enter
clinic
trial
phase
tabl
oncolyt
activ
mv
demonstr
least
differ
cancer
type
furthermor
attenu
mv
use
worldwid
vaccin
children
excel
safeti
profil
revers
wt
mv
make
attract
oncolyt
vector
compar
oncolyt
virus
use
vaccin
attenu
oncolyt
mv
vector
retain
characterist
enabl
replic
human
host
compar
replic
defect
viral
vector
likelihood
exposur
environ
around
patient
increas
howev
dissemin
viral
vector
patient
environ
advers
event
per
se
impact
mostli
depend
characterist
recombin
vector
pathogen
infecti
dose
transmiss
mode
avail
effect
prophylaxi
treatment
suscept
disinfect
vector
use
develop
attenu
recombin
mv
vaccin
infecti
diseas
enter
clinic
trial
phase
engin
revers
genet
cdna
differ
measl
vaccin
strain
describ
radeck
et
al
addit
transcript
unit
atu
introduc
viral
genom
order
construct
vector
express
sequenc
correspond
foreign
antigen
tabl
summar
clinic
preclin
studi
perform
use
recombin
mv
vector
prophylaxi
vaccin
candid
infecti
diseas
although
wt
mv
result
potenti
seriou
infecti
diseas
attenu
mv
strain
signific
safeti
record
million
vaccin
dose
safe
administr
use
howev
fatal
infect
document
immunodefici
vaccin
children
vaccin
adult
aid
administr
hightit
ht
edmonstonzagreb
vaccin
area
high
incid
measl
children
younger
month
shown
increas
incid
femal
mortal
investig
suggest
ht
measl
vaccin
caus
immun
suppress
similar
measl
infect
review
summar
ht
studi
suggest
ht
vaccin
unlik
caus
immunosuppress
inde
effect
found
studi
moreov
ht
studi
excess
mortal
rate
show
increas
femal
mortal
rate
could
due
environment
contextu
condit
accord
high
attenu
profil
histori
safe
use
mv
attenu
strain
current
use
measl
vaccin
could
classifi
agent
class
risk
strain
nonpathogen
human
harm
environ
present
neglig
risk
contain
use
mvedm
b
strain
also
classifi
class
risk
mvedm
strain
reactogen
caus
fever
rash
children
howev
strain
abl
caus
diseas
transmiss
person
reconvers
wildtyp
addit
alreadi
mention
mv
genom
stabl
revers
measl
vaccin
strain
pathogen
subsequ
transmiss
individu
date
report
addit
use
vaccin
measl
attenu
mv
use
backbon
develop
prophylact
vaccin
recombin
oncolyt
vector
mv
vector
shown
stabli
express
larg
heterolog
antigencod
sequenc
kb
long
unlik
primari
strain
attenu
vaccin
strain
caus
immunosuppress
addit
mv
infect
cell
immun
system
includ
macrophag
dc
thu
provid
opportun
deliv
antigen
directli
effect
antigen
present
cell
major
advantag
vaccin
vector
sever
studi
provid
good
indic
clinic
safeti
efficaci
vector
preclin
studi
test
recombin
mv
vaccin
prophylaxi
sarscov
chikungunya
viru
dengu
viru
west
nile
viru
infecti
diseas
cancer
tabl
mv
recombin
vector
elicit
strong
longterm
hivspecif
neutral
antibodi
cellular
immun
respons
even
presenc
preexist
immun
mv
arbovirus
west
nile
viru
dengu
viru
sarscov
anim
model
strong
capac
rais
tcell
respons
persist
long
term
lymphoid
organ
hallmark
live
attenu
vaccin
mv
particularli
effici
gener
live
long
memori
cell
help
maintain
neutral
antibodi
prevent
reinfect
longterm
protect
immun
human
express
foreign
transgen
still
evalu
phase
clinic
studi
recombin
mv
use
immun
healthi
peopl
ongo
result
phase
clinic
trial
vaccin
candid
mvchik
use
immun
peopl
chikungunya
viru
avail
hazard
relat
transgen
recombin
mv
vector
use
risk
assess
also
take
account
potenti
risk
associ
transgen
vaccin
candid
develop
revers
genet
cdna
schwarz
strain
genet
modifi
express
hiv
antigen
singl
fusion
protein
compris
clade
antigen
encod
gag
revers
transcriptas
encod
pol
regulatori
protein
nef
structur
protein
present
capsid
associ
viral
protein
result
matrix
protein
envelop
capsid
ensur
integr
virion
nef
act
increas
infect
viral
particl
reduc
express
receptor
molecul
cell
surfac
final
revers
transcriptas
enzym
use
gener
cdna
viral
rna
fusion
protein
alon
administ
vaccin
candid
intramuscular
rout
healthi
hiv
seroneg
adult
toxic
allerg
effect
observ
phase
clinic
trial
vaccin
candid
mvchik
also
develop
schwarz
strain
vector
backbon
modifi
express
structur
gene
chikungunya
viru
structur
protein
capsid
c
envelop
glycoprotein
small
peptid
allow
format
selfassembl
viru
particl
vlp
mimic
alphaviru
extern
structur
structur
protein
administ
vaccin
candid
healthi
adult
phase
trial
shown
safe
well
toler
furthermor
result
phase
trial
show
mvchik
safe
overal
accept
toler
profil
administr
healthi
human
mv
vector
ptmmvschw
use
construct
mvchik
contain
infecti
cdna
correspond
antigenom
schwarz
vaccin
strain
addit
transcript
unit
atu
introduc
viral
genom
order
construct
vector
express
sequenc
correspond
fusion
protein
structur
protein
chik
mvchik
atu
introduc
plasmid
backbon
sitedirect
mutagenesi
mv
p
gene
rescu
recombin
viru
plasmid
perform
use
helpercellbas
rescu
system
cell
mv
edm
b
strain
use
virotherapi
modifi
express
report
protein
mvcea
express
solubl
ntermin
domain
human
carcinoembryon
antigen
cea
cea
biolog
inert
tumor
marker
minim
immunogen
phase
clinic
trial
mvcea
administr
intraperiton
rout
patient
doselimit
toxic
treatmentinduc
immunosuppress
observ
cea
express
allow
noninvas
monitor
viral
gene
express
provid
inform
anatom
local
viral
infect
cell
enhanc
oncolyt
effect
viral
vector
therefor
mv
modifi
express
anoth
report
protein
sodium
iodid
symport
ni
ni
protein
membran
ion
channel
normal
express
thyroid
mammari
gland
stomach
salivari
tissu
express
ni
allow
cell
activ
transport
ion
cell
may
use
therapeut
transgen
capabl
increas
oncolyt
potenc
mvni
facilit
intracellular
entri
radioisotop
caus
direct
radiat
damag
tumor
cell
therebi
viru
deriv
edmonston
vaccin
lineag
nse
strain
rescu
use
pseudoreceptor
star
tag
retarget
system
propag
verohi
cell
viral
h
protein
contain
mutat
slamablat
mutat
also
contain
gfp
facilit
viral
rescu
allow
visual
infect
vitro
vivo
rescu
system
use
chine
hamster
ovari
cell
express
chohslam
recombin
vaccinia
viru
lister
strain
use
vaccin
smallpox
erad
programm
enhanc
therapeut
efficaci
radiovirotherapi
phase
clinic
trial
mvni
administ
intraperiton
rout
patient
doselimit
toxic
observ
mvcea
mvni
achiev
via
introduct
transgen
addit
transcript
unit
upstream
viral
n
gene
mvcea
downstream
viral
h
gene
h
l
gene
mvni
preclin
studi
mvni
administ
intraven
squirrel
monkey
measlessuscept
transgen
mice
toxic
observ
prematur
unschedul
death
studi
advers
clinic
sign
meaning
effect
bodi
weight
temperatur
seen
mvni
treatmentrel
effect
observ
hematolog
clinic
chemistri
thyroid
hormon
cytokin
paramet
reticulocyt
count
transient
suppress
cyclophosphamidetr
anim
treatmentrel
lesion
seen
anim
time
necropsi
histopatholog
chang
observ
organ
test
phase
clinic
trial
therefor
initi
determin
maximum
toler
dose
intraven
administr
mvni
patient
advanc
refractori
multipl
myeloma
preliminari
data
patient
studi
report
patient
seroneg
prior
measl
exposur
receiv
highest
feasibl
dose
level
tcid
tissu
cultur
infecti
dose
secondari
effect
becam
febril
tachycard
hypotens
sever
nausea
vomit
toxic
resolv
within
first
week
therapi
probabl
due
high
dose
recombin
viru
administr
combin
absenc
preexist
immun
insert
vlp
cea
ni
current
use
phase
iii
clinic
trial
insert
use
combin
oncolyt
mv
test
preclin
studi
review
see
msaouel
et
al
safeti
profil
still
character
take
account
express
gene
product
may
intrins
hazard
properti
toxic
allergen
properti
gene
product
may
consid
potenti
hazard
particular
context
gene
therapi
use
viral
vector
review
bergman
et
al
van
den
akker
et
al
also
discuss
insert
unknown
novel
characterist
produc
synthet
biolog
could
consid
potenti
hazard
final
hazard
relat
transgen
also
depend
condit
use
dose
administr
rout
express
level
transgen
foreign
gene
could
potenti
lead
retarget
oncolyt
mv
vector
cell
increas
specif
tumor
cell
mv
vector
retarget
specif
tumor
cell
link
singlechain
antibodi
singl
chain
fragment
variabl
scfv
natur
occur
ligand
viru
attach
h
glycoprotein
display
viru
surfac
ablat
receptor
bind
site
vector
allow
entri
cell
express
receptor
scfv
ligand
link
h
varieti
scfv
display
h
differ
receptor
tabl
broaden
viral
tropism
molecul
express
lumin
endotheli
surfac
tumor
neovascular
may
increas
target
viral
deliveri
tumor
site
follow
system
administr
retarget
attenu
mv
edm
vector
lack
neurotox
activ
even
administ
directli
cn
ifn
type
receptor
defici
ifnar
ko
ge
transgen
mice
sensit
model
viral
neurotox
howev
toxic
retarget
vector
evalu
nonhuman
primat
initi
clinic
studi
transgen
mice
express
human
receptor
final
recombin
mv
show
excel
stabil
transgen
express
variou
gene
combin
gene
express
stabli
mv
vector
passag
possibl
recombin
virus
genet
stabil
mv
strain
conclus
evid
date
genet
recombin
event
mv
vaccin
wt
strain
peopl
coinfect
virus
recombin
effici
mean
rapid
genet
chang
mani
virus
occur
paramyxovirus
recombin
virus
isol
natur
infect
unlik
rna
virus
influenza
hiv
mv
vaccin
strain
demonstr
high
genet
stabil
even
prolong
replic
human
host
consequ
probabl
gener
mutant
strain
low
influenc
preexist
immun
like
viral
vector
mv
vector
efficaci
induc
protect
immun
answer
could
affect
preexist
immun
among
human
popul
howev
numer
studi
shown
revaccin
alreadi
immun
individu
result
boost
antimv
antibodi
indic
live
vaccin
replic
despit
preexist
immun
likewis
presenc
matern
antimv
antibodi
shown
limit
induct
humor
cmi
respons
immun
infant
moreov
vaccin
preimmun
mice
primat
recombin
mv
express
hiv
antigen
shown
induct
antihiv
env
antibodi
presenc
antimv
antibodi
anoth
studi
mice
immun
recombin
mvsar
vector
develop
sarsspecif
immun
respons
presenc
antimv
immun
rout
administr
vector
could
also
influenc
immun
respons
vaccin
strain
mvb
mv
vector
develop
vaccin
strain
could
administr
aerosol
could
therefor
circumv
system
mv
preimmun
effici
parenter
administr
studi
evalu
safeti
aerosol
measl
vaccin
identifi
sever
side
effect
howev
aerosol
measl
vaccin
could
trigger
exacerb
asthma
young
children
observ
intranas
administr
attenu
influenza
vaccin
antimeasl
immun
enhanc
safeti
oncolyt
mv
prerequisit
major
mv
virotherapi
trial
howev
neutral
antibodi
may
limit
infect
tumor
cell
mv
inde
cellassoci
virus
protect
antibodi
neutral
test
overcom
antivir
preexist
immun
mesenchym
stem
cell
msc
transduc
mvni
inject
ovarian
tumor
xenograft
mvni
transduc
msc
significantli
extend
surviv
measl
immun
tumor
bear
mice
contrast
mvni
inject
alon
mesenchym
stem
cell
transduc
mvni
current
test
phase
iii
clinic
trial
risk
classif
recombin
mv
vector
depend
natur
vector
also
take
account
potenti
risk
associ
insert
gene
recommend
classifi
mvchik
class
risk
inde
mv
strain
backbon
deriv
attenu
measl
vaccin
strain
protein
vlp
known
toxic
allerg
effect
administr
human
recombin
vector
mvcea
mvni
also
classifi
class
risk
base
class
risk
edm
b
strain
use
vector
backbon
reason
think
presenc
cea
ni
could
chang
safeti
profil
recombin
viru
import
step
risk
assess
viral
vector
evalu
exposur
pathway
wherebi
personnel
nonpati
andor
environ
may
expos
recombin
mv
administr
patient
biodistribut
defin
dispers
vector
within
patient
bodi
site
administr
inde
presenc
viral
vector
organ
might
indic
potenti
shed
correspond
dissemin
viral
vector
form
environ
via
excreta
urin
faec
sweat
saliva
nasopharyng
fluid
blood
semen
treat
patient
biodistribut
shed
mv
vector
depend
dose
rout
administr
mv
strain
use
wildtyp
mv
strain
use
primarili
receptor
express
lymphocyt
thymocyt
macrophag
matur
dc
cell
receptor
express
epitheli
cell
viral
entri
host
cell
infect
wt
mv
thought
begin
infect
dc
respiratori
tract
follow
lymphoid
organ
phase
local
replic
follow
primari
secondari
viremia
viral
spread
multipl
epitheli
tissu
includ
skin
kidney
gastrointestin
tract
liver
respiratori
tract
shed
viru
occur
nasopharynx
natur
infect
mv
also
isol
urin
rash
onset
mv
rna
persist
multipl
site
mani
month
resolut
rash
appar
recoveri
proport
children
experiment
infect
rhesu
macaqu
mv
show
persist
viral
rna
blood
respiratori
tract
lymph
node
characterist
primari
mv
infect
addit
receptor
use
wt
mv
attenu
mv
strain
use
receptor
viral
entri
host
cell
therefor
expect
wider
tropism
wt
mv
strain
biodistribut
attenu
mv
edm
b
strain
compar
wt
mv
cynomoglu
macaqu
experiment
infect
via
intratrach
aerosol
rout
virus
predominantli
infect
alveolar
macrophag
dc
lung
howev
strikingli
wt
mv
caus
viremia
dissemin
lymphoid
tissu
respiratori
submucosa
skin
mechan
must
oper
vivo
suppress
growth
viru
capabl
use
receptor
also
import
take
account
standard
rout
administr
liveattenu
mv
vaccin
subcutan
rout
evalu
studi
intramuscular
vaccin
macaqu
mv
edmonstonzagreb
strain
express
gfp
demonstr
muscl
cell
infect
dendrit
cell
macrophag
predominantli
target
cell
publish
data
shed
mv
vaccin
strain
limit
measl
vaccin
human
mv
rna
could
detect
urin
late
post
immun
rare
detect
throat
nasopharyng
secret
morfin
et
al
report
case
measl
schwarz
viru
isol
throat
swab
child
vaccin
studi
realiz
children
present
symptomat
post
vaccin
excret
mv
nasopharynx
show
subcutan
inject
attenu
mv
schwarz
strain
result
respiratori
excret
viru
howev
person
person
transmiss
measl
vaccin
never
report
biodistribut
candid
vaccin
similar
parent
mv
schwarz
strain
monkey
immun
intramuscular
rout
vaccin
replic
preferenti
secondari
lymphoid
organ
epitheliumrich
tissu
assess
potenti
shed
parent
schwarz
vaccin
strain
vaccin
candid
excret
bodi
fluid
monkey
immun
vaccin
strain
test
presenc
mv
viral
sequenc
rtqpcr
assay
time
point
shed
analysi
perform
mv
viral
rna
detect
day
expect
peak
viremia
biolog
fluid
sampl
immun
monkey
howev
none
sampl
contain
infecti
viru
indic
shed
infecti
viru
particl
observ
either
vaccin
introduct
hiv
fusion
protein
alter
tropism
parent
strain
shed
capac
data
avail
regard
biodistribut
shed
mvchik
howev
alter
tropism
expect
vector
contain
gene
code
structur
protein
chikungunya
viru
regard
recombin
oncolyt
mv
vector
describ
follow
data
avail
mvcea
mvni
order
maxim
viral
infect
tumor
cell
mvcea
mvni
administr
intraperiton
rout
patient
recurr
ovarian
cancer
preclin
studi
perform
measl
ifnar
ko
ge
mice
evid
viral
replic
outsid
periton
caviti
ie
brain
heart
skelet
muscl
phase
clinic
studi
women
administ
low
level
mvcea
genom
found
rtqpcr
peripher
blood
mononuclear
cell
pbmc
asymptomat
patient
sixteen
women
receiv
mvni
detect
viral
genom
peripher
blood
observ
shed
oncolyt
mv
also
evalu
preclin
clinic
studi
phase
clinic
studi
viral
rna
urin
saliva
observ
intraperiton
administr
mvcea
mvni
one
phase
clinic
trial
list
tabl
mvni
administr
intraven
rout
without
pretreat
cyclophosphamid
addit
chemotherapeut
activ
cyclophosphamid
immunosuppress
agent
therefor
potenti
prolong
enhanc
viral
dissemin
replic
tumor
evalu
biodistribut
intraven
mvni
administr
ifnar
ko
ge
mice
pretreat
cyclophosphamid
demonstr
alter
biodistribut
mvnisinfect
cell
kinet
mvni
elimin
viru
sporad
detect
rtqpcr
brain
cyclophosphamidepretr
mice
wherea
treat
cyclophosphamid
remain
neg
two
patient
advanc
refractori
multipl
myeloma
treat
intraven
infus
mvni
radioiodin
spectct
scan
provid
clear
evid
tumortarget
mvni
infect
propag
mvni
infect
tumor
cell
evid
spread
mvni
tumor
adjac
normal
tissu
shed
mvni
administ
intraven
rout
alon
pretreat
cyclophosphamid
evalu
rtqpcr
viral
rna
detect
buccal
swab
monkey
intraven
administr
mvni
higher
level
viru
rna
detect
buccal
swab
cyclophosphamid
treat
monkey
viral
rna
remain
detect
longer
period
time
indic
drug
enhanc
propag
vector
anim
measl
viru
transcript
still
detect
circul
cell
one
patient
week
intraven
infus
mvni
cours
clinic
trial
possibl
consequ
leakag
vector
outsid
patient
bodi
may
includ
exampl
advers
effect
associ
infect
personnel
peopl
gener
come
contact
vaccin
individu
howev
import
take
account
individu
industri
countri
immun
wt
measl
viru
result
natur
infect
vaccin
moreov
mention
measl
viru
rapidli
degrad
environ
consequ
dissemin
also
depend
characterist
recombin
vector
particular
safeti
profil
transgen
shown
safe
manipul
might
lead
exposur
recombin
mv
vector
eg
prepar
viral
vector
administr
patient
wast
dispos
direct
exposur
may
also
result
accident
inocul
personnel
treatment
patient
via
droplet
aerosol
contact
mucou
membran
nonintact
skin
eye
risk
pierc
needl
injuri
due
sharp
cut
broken
vial
greatest
personnel
handl
vial
syring
medic
paramed
staff
peopl
visit
treat
patient
could
also
expos
contamin
materi
wast
materi
spoil
surfac
exposur
pathway
reduc
elimin
applic
appropri
risk
manag
strategi
attenu
mv
recombin
vector
use
clinic
set
contain
condit
appropri
contain
measur
protect
human
health
environ
implement
result
risk
assess
take
account
characterist
biolog
agent
manipul
natur
transgen
natur
activ
four
contain
level
stringent
defin
eu
legisl
consist
combin
technic
characterist
facil
safeti
equip
laboratori
practic
oper
procedur
wast
manag
procedur
attenu
mvchik
vaccin
candid
histori
safe
use
mv
schwarz
strain
allow
handl
recombin
viru
clinic
set
mention
addit
transgen
chang
safeti
profil
also
recommend
handl
mvcea
mvni
oncolyt
vector
transduct
msc
cell
recombin
mvni
carri
manipul
mesenchym
stem
cell
primari
cell
cultur
obtain
directli
organ
tissu
presenc
adventiti
contamin
agent
constitut
main
hazard
character
finit
life
span
time
avail
character
detect
contamin
agent
remain
limit
therefor
primari
cell
cultur
deriv
human
must
transduc
manipul
class
ii
biosafeti
cabinet
guarante
product
steril
personnel
wear
glove
prevent
manag
risk
associ
dissemin
recombin
mv
vector
environ
viral
vector
administr
applic
specif
work
practic
appli
personnel
wear
person
protect
equip
prevent
manag
risk
oper
produc
aerosol
punctur
vial
limit
strictli
contain
prepar
administr
recombin
mv
vector
consequ
prepar
gm
vector
prefer
perform
class
ii
biosafeti
cabinet
personnel
administr
vector
wear
adequ
protect
cloth
lab
coat
glove
goggl
mask
work
needl
sharp
object
strictli
limit
worker
never
recap
remov
needl
syring
spill
inactiv
appropri
disinfect
eg
sodium
hypochlorit
extemporan
prepar
allow
suffici
contact
time
dispos
contamin
wast
person
protect
equip
inactiv
use
appropri
method
autoclav
inciner
dispos
potenti
contamin
nondispos
materi
eg
materi
use
transport
prepar
administr
gm
vector
instrument
surfac
need
properli
decontamin
incid
occur
could
lead
infect
eg
breakag
vial
contain
vector
pierc
needl
applic
first
aid
perform
ie
flush
eye
ocular
exposur
place
absorb
tissu
affect
area
order
absorb
viral
particl
appli
disinfect
directli
tissu
remov
tissu
wash
skin
thoroughli
follow
report
supervisor
personnel
manipul
recombin
vector
person
close
contact
treat
patient
vaccin
measl
inject
recombin
mv
treat
patient
avoid
contact
immunosuppress
individu
individu
lack
protect
immun
minimum
saliva
urin
blood
pbmc
test
neg
viru
whichev
longer
number
patient
treat
differ
mv
strain
specif
clinic
indic
increas
clinic
inform
regard
likelihood
durat
shed
accumul
biosafeti
guidelin
expect
evolv
mv
human
viru
known
anim
reservoir
risk
anim
plant
attenu
mv
one
effect
safe
human
vaccin
use
provid
longlast
protect
attenu
mv
wide
use
recombin
vector
vaccin
variou
infecti
diseas
cancer
virotherapi
measl
viru
cytoplasm
replic
cycl
elimin
possibl
integr
host
cell
dna
avoid
possibl
insert
mutagenesi
furthermor
mv
genom
stabl
mv
vector
shown
stabli
express
larg
size
foreign
insert
genet
sequenc
present
discuss
paper
sever
biosafeti
issu
need
consid
care
perform
clinic
trial
recombin
attenu
mv
vector
perform
comprehens
risk
assess
mv
vector
current
use
clinic
trial
prophylact
vaccin
oncolyt
vector
conclud
mv
vector
belong
class
risk
human
order
maxim
risk
mitig
avoid
dissemin
environ
mv
vector
manipul
contain
level
note
activ
microorgan
genet
modifi
gmm
pathogen
use
specif
contain
measur
use
limit
contact
provid
high
level
safeti
gener
popul
environ
potenti
conflict
interest
disclos
